Crispr Gene Editing In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated nucleases (such as Cas9) are programmable genome-editing systems with major translational potential for neurodegenerative diseases. CRISPR approaches are being explored to model disease biology, silence toxic gain-of-function alleles, and correct pathogenic variants in genes implicated in Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, and Huntington's Disease.
The canonical CRISPR-Cas9 system uses a single guide RNA (sgRNA) to direct the Cas9 endonuclease to a complementary genomic target flanked by a protospacer adjacent motif (PAM). Cas9 introduces a double-strand break (DSB) at the target site, which the cell repairs through either non-homologous end joining (NHEJ) — often resulting in insertions or deletions (indels) that disrupt gene function — or homology-directed repair (HDR), which can introduce precise sequence changes when a donor template is provided Jinek et al., 2012. For neurodegenerative diseases, NHEJ-mediated gene disruption is used to silence toxic gain-of-function alleles, while HDR enables correction of point mutations in genes such as [APP[/genes/app, [PSEN1[/genes/psen1, [SOD1[/proteins/sod1-protein, and [HTT[/genes/htt.
Second-generation CRISPR technologies have addressed key limitations of nuclease-based editing. Base editors (cytosine and adenine base editors) enable direct conversion of one nucleotide to another without creating DSBs, reducing the risk of large deletions and chromosomal rearrangements [Komor et al., 2016]https://doi.org/10.1038/nature17946). Prime editors use a Cas9 nickase fused to an engineered reverse transcriptase, allowing all 12 possible point mutations plus small insertions and deletions without DSBs or donor templates [Anzalone et al., 2019]https://doi.org/10.1038/s41586-019-1711-4). CRISPRi (interference) and CRISPRa (activation) use catalytically dead Cas9 (dCas9) fused to transcriptional repressors or activators, enabling reversible modulation of gene expression without permanent genome modification — particularly attractive for the central nervous system where irreversible changes carry heightened risk.
CRISPR approaches for [Alzheimer's disease[/diseases/alzheimers target multiple pathological pathways. Disruption of the [BACE1[/entities/bace1 gene, which cleaves [amyloid precursor protein[/genes/app to generate [amyloid-beta[/entities/amyloid-beta, has shown reduced [amyloid-beta[/entities/amyloid-beta production in mouse models Park et al., 2019. CRISPR-based conversion of the [APOE[/genes/apoe. For familial AD caused by [PSEN1[/genes/psen1 and [PSEN2[/genes/psen2 mutations, prime editing offers the precision needed to correct over 300 known pathogenic variants while preserving normal presenilin function.
In [Parkinson's disease[/diseases/parkinsons, CRISPR targets include the [SNCA[/genes/snca gene encoding [alpha-synuclein[/proteins/alpha-synuclein/proteins/alpha, whose duplication, triplication, or missense mutations (A53T, A30P, E46K) cause autosomal dominant PD. CRISPRi-mediated silencing of SNCA reduces [alpha-synuclein[/proteins/alpha-synuclein expression and aggregation in [dopaminergic neurons[/cell-types/dopaminergic-neurons of the [substantia nigra[/brain-regions/substantia-nigra, the population most vulnerable in PD Kantor et al., 2018. CRISPR has also been used to correct [LRRK2[/genes/lrrk2 G2019S mutations, the most common genetic cause of familial PD, in patient-derived [iPSCs[/technologies/ipsc-disease-models. Additionally, knockout of [PINK1[/genes/pink1 and [PRKN[/genes/prkn via CRISPR has generated improved cellular models for studying mitochondrial dysfunction in PD.
For [ALS[/diseases/als, CRISPR-mediated disruption of mutant [SOD1[/proteins/sod1-protein has shown striking efficacy in transgenic mouse models, extending survival by up to 25% when delivered via adeno-associated virus (AAV) vectors Gaj et al., 2017. The [C9orf72[/genes/c9orf72 hexanucleotide repeat expansion, the most common genetic cause of both familial ALS and [frontotemporal dementia[/diseases/ftd, has been targeted by CRISPR excision of the expanded repeat or CRISPRi-mediated silencing of the sense and antisense transcripts that produce toxic dipeptide repeat proteins. CRISPR editing of [FUS[/entities/fus and [TARDBP[/genes/tardbp (encoding [TDP-43) mutations has also been explored in iPSC-derived [motor neurons[/cell-types/motor-neurons.
[Huntington's disease[/mechanisms/huntington-pathway, caused by CAG trinucleotide repeat expansion in the [HTT[/genes/htt gene, is a prime candidate for CRISPR therapy because it follows a monogenic, autosomal dominant inheritance pattern. Allele-selective CRISPR strategies target single-nucleotide polymorphisms (SNPs) linked to the expanded allele, preserving normal [huntingtin[/proteins/huntingtin function while eliminating the toxic mutant protein [Shin et al., 2016]https://doi.org/10.1093/hmg/ddw286). In HD mouse models, AAV-delivered CRISPR targeting the [HTT[/genes/htt promoter region with CRISPRi has achieved sustained reduction of mutant [huntingtin[/proteins/huntingtin levels with accompanying behavioral improvement.
Effective delivery of CRISPR components across the [blood-brain barrier[/entities/blood-brain-barrier remains one of the greatest challenges for clinical translation. AAV vectors — particularly AAV9 and AAVrh10 — can transduce [neurons[/entities/neurons and [glial cells[/cell-types/astrocytes after intrathecal or intravenous injection, but have limited cargo capacity (~4.7 kb), which is insufficient for SpCas9 plus its sgRNA in a single vector [Wang et al., 2020]https://doi.org/10.1038/s41587-019-0344-3). Split-intein approaches and smaller Cas orthologs (SaCas9, CjCas9, Cas12a) address this constraint. Lipid nanoparticles (LNPs) offer non-viral delivery with reduced immunogenicity and the ability to carry larger payloads, including mRNA encoding Cas9 and the sgRNA. Extracellular vesicles and engineered exosomes represent emerging delivery platforms that exploit natural membrane-trafficking pathways to cross the [Blood-Brain Barrier[/entities/blood-brain-barrier Akyuz et al., 2024. Direct stereotactic injection into specific brain regions (e.g., [hippocampus[/brain-regions/hippocampus, [striatum[/brain-regions/striatum provides localized delivery but is invasive and impractical for diffuse diseases like AD.
Unintended editing at genomic sites similar to the target sequence remains a critical concern, especially for irreversible applications in the brain. Whole-genome sequencing studies have identified off-target cleavage at rates varying from negligible to clinically significant, depending on sgRNA design and Cas variant. High-fidelity Cas9 variants (eSpCas9, HiFi-Cas9) and truncated sgRNAs reduce off-target activity, while unbiased detection methods such as GUIDE-seq and CIRCLE-seq enable comprehensive profiling before clinical translation.
Bacterial-derived Cas proteins elicit humoral and cellular immune responses in humans. Pre-existing anti-Cas9 antibodies have been detected in 58-79% of the human population, and T-cell responses against Cas9 peptides can eliminate edited cells [Charlesworth et al., 2019]https://doi.org/10.1038/s41591-018-0326-x). Strategies to mitigate immunogenicity include transient mRNA delivery (limiting Cas9 expression duration), immunosuppressive regimens, and engineering of less immunogenic Cas orthologs.
Achieving uniform editing across the billions of [neurons[/entities/neurons in the human brain is not feasible with current technology. Therapeutic strategies must therefore focus on diseases where partial reduction of a toxic protein (e.g., 50-70% knockdown of mutant [HTT[/genes/htt or SOD1) is sufficient for clinical benefit, or on localized editing within specific vulnerable brain regions.
Germline editing for neurodegenerative diseases raises fundamental ethical questions about heritability, consent, and equitable access. Current consensus, reinforced by the WHO Global Standards for Governance of Human Genome Editing (2021), restricts clinical applications to somatic editing while calling for robust international oversight frameworks.
As of 2025, no CRISPR-based therapy has entered clinical trials for neurodegenerative diseases, though several preclinical programs are advancing rapidly. Intellia Therapeutics and CRISPR Therapeutics are developing in vivo CRISPR platforms for CNS targets. The success of CRISPR-based therapies in other domains — including FDA-approved Casgevy (exagamglogene autotemcel) for sickle cell disease — demonstrates the feasibility of clinical-grade CRISPR editing and provides a regulatory pathway model for future neurodegeneration applications Frangoul et al., 2021. Ongoing advances in delivery technology, editing precision, and biomarker-guided patient selection are expected to bring the first neurodegeneration CRISPR trials to the clinic within the next 3-5 years.
The study of Crispr Gene Editing In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.